Primary cutaneous CD30+ lymphoproliferative disorders: new insights into biology and therapy.
The spectrum of CD30+ lymphoproliferative diseases of the skin includes CD30+ cutaneous anaplastic large cell lymphoma, lymphomatoidpapulosis, as well as borderline cases. These entities constitute the second most common group of cutaneous lymphomas according to the newly revised World Health Organization and European Organisation for Research and Treatment of Cancer consensus classification. Recent progress in immune and molecular biology, and identification of therapeutic targets have increased our understanding of these diseases and have led to novel treatment approaches. This review will provide an update on recent findings of immunologic, molecular, cytogenetic features and treatment strategies for patients with CD30+ lymphoproliferative diseases.
Querfeld
Christiane
C
Robert H. Lurie Comprehensive Cancer Center, Northwestern University Chicago, Illinois 60611, USA. c-querfeld@northwestern.edu
Kuzel
Timothy M
TM
Guitart
Joan
J
Rosen
Steven T
ST
D003131:Combined Modality Therapy; D006801:Humans; D017730:Ki-1 Antigen / Q000378:metabolism; D017728:Lymphoma, Large-Cell, Anaplastic / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D016410:Lymphoma, T-Cell, Cutaneous / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D017731:Lymphomatoid Papulosis / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D011379:Prognosis; D012878:Skin Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy
D017730:Ki-1 Antigen